Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function

被引:16
作者
Davis, KR
Pearson, H
Moat, S
Bonham, JR
Donnelly, R
机构
[1] Univ Nottingham, Sch Med & Surg Sci, Nottingham NG7 2RD, England
[2] Sheffield Childrens Hosp, Dept Chem Pathol, Sheffield, S Yorkshire, England
关键词
endothelial dysfunction; homocysteine; laser Doppler fluximetry; microvascular;
D O I
10.1046/j.0306-5251.2001.01447.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Raised homocysteine (hcy) levels are associated with premature coronary artery disease, but the underlying vascular mechanism and the extent to which hcy affects small vessel vasodilator responses (especially non-nitric oxide mediated pathways) are unclear. Methods This double-blind, placebo-controlled crossover study in 14 healthy male subjects evaluated the effects of single-dose oral methionine 15 g (to induce acute hyperhomocysteinaemia) on cutaneous microvascular vasodilator responses to incremental-dose iontophoretic administration of acetylcholine (Ach) and sodium nitroprusside (SNP) using laser Doppler fluximetry (LDF), and the effects on von Willibrand factor (vWF) levels and systemic haemodynamics. Results Methionine administration produced a three fold rise in plasma hcy levels at 8 h, which was accompanied by a significant increase in pulse pressure (53 vs 49 mmHg, P < 0.05) but no change in heart rate. Acute hyperhomocysteinaemia had no significant effect on incremental microvascular vasodilator dose-response curves to Ach and SNP, or circulating levels of vWF. Conclusions The present study shows that acute hyperhomocysteinaemia increases pulse pressure (a marker of large vessel stiffness) but has no effect on endothelial-dependent (non-NO-mediated) microvascular vasodilation.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 36 条
[1]   SERUM TOTAL HOMOCYSTEINE AND CORONARY HEART-DISEASE [J].
ARNESEN, E ;
REFSUM, H ;
BONAA, KH ;
UELAND, PM ;
FORDE, OH ;
NORDREHAUG, JE .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1995, 24 (04) :704-709
[2]   Pulse pressure -: A predictor of long-term cardiovascular mortality in a French male population [J].
Benetos, A ;
Safar, M ;
Rudnichi, A ;
Smulyan, H ;
Richard, JL ;
Ducimetière, P ;
Guize, L .
HYPERTENSION, 1997, 30 (06) :1410-1415
[3]   Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia - An effect reversible with vitamin C therapy [J].
Chambers, JC ;
McGregor, A ;
Jean-Marie, J ;
Obeid, OA ;
Kooner, JS .
CIRCULATION, 1999, 99 (09) :1156-1160
[4]  
Davis KR, 2001, BRIT J OBSTET GYNAEC, V108, P610
[5]   Hyperhomocysteinemia as a risk factor for deep-vein thrombosis [J].
denHeijer, M ;
Koster, T ;
Blom, HJ ;
Bos, GMJ ;
Briet, E ;
Reitsma, PH ;
Vandenbroucke, JP ;
Rosendaal, FR .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :759-762
[6]   An alternative view of homocysteine [J].
Dudman, NPB .
LANCET, 1999, 354 (9195) :2072-2074
[7]  
Fassbender K, 1999, LANCET, V353, P1586
[8]   Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].
Graham, IM ;
Daly, LE ;
Refsum, HM ;
Robinson, K ;
Brattstrom, LE ;
Ueland, PM ;
PalmaReis, RJ ;
Boers, GHJ ;
Sheahan, RG ;
Israelsson, B ;
Uiterwaal, CS ;
Meleady, R ;
McMaster, D ;
Verhoef, P ;
Witteman, J ;
Rubba, P ;
Bellet, H ;
Wautrecht, JC ;
deValk, HW ;
Luis, ACS ;
ParrotRoulaud, FM ;
Tan, KS ;
Higgins, I ;
Garcon, D ;
Medrano, MJ ;
Candito, M ;
Evans, AE ;
Andria, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781
[9]   Homocysteine and vascular disease [J].
Hankey, GJ ;
Eikelboom, JW .
LANCET, 1999, 354 (9176) :407-413
[10]  
HEINECKE JW, 1993, J LIPID RES, V34, P2051